Tempest Therapeutics, Inc. TPST
Tempest Therapeutics, Inc. (Nasdaq: TPST) is an oncology drug developer. Its lead program, TPST-2003, is in Phase 1 for Relapsed/refractory multiple myeloma; POEMS syndrome. Its next catalyst on record is TPST-4003: First patient dosing in China IIT (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TPST-4003 — First patient dosing in China IIT (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| amezalpat (TPST-1120) | 1L HCC | small molecule | Phase 2 |
| TPST-1495 | FAP | small molecule | Phase 2 |
| TPST-2003 (autologous CD19/BCMA CAR-T) | rrMM, POEMS | cell therapy | Phase 1 |
| TPST-4003 (in vivo CD19/BCMA CAR-T) | MG / MS (China IIT) | cell therapy | Pre-clinical |
| TPST-3003 | Allogeneic CD19/BCMA CAR-T | cell therapy | Pre-clinical |
| TPST-2206 | CD70 CAR-T | cell therapy | Pre-clinical |
| TPST-3206 | Allogeneic CD70 CAR-T | cell therapy | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.